Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578723 | 0.85 | TDP1 (0.33) | TDP1TSHRALDH1A1THRB | |
| SCHEMBL7542166 | 0.81 | TGFBR1 (0.32) | TGFBR1 | |
| SCHEMBL2344897 | 0.79 | — | — | |
| SCHEMBL5753839 | 0.79 | TDP1 (0.36) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL9015316 | 0.78 | TDP1 (0.38) | TGFBR1TDP1ADRA1ATSHR | |
| SCHEMBL27653781 | 0.78 | TDP1 (0.40) | TGFBR1TDP1TSHRTET2TET3 | |
| SCHEMBL5830000 | 0.78 | CA2 (0.47) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL2408287 | 0.76 | — | — | |
| SCHEMBL3504770 | 0.76 | CHRM1 (0.38) | TDP1CHRM1AKR1A1CHRM3HTR2A | |
| Ethylmalonate SCHEMBL28635933 | 0.75 | HDAC1 (0.41) | TDP1CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11602515-B2 | Pharmaceutical compositions comprising dimethyl fumarate | ALMIRALL, S.A. (ES) | 2023-03-14 | — | — | US | disclosed |
| US-20210330628-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | ALMIRALL, S.A. (ES) | 2021-10-28 | — | — | US | disclosed |
| EP-3079666-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL SA (ES) | 2021-02-03 | — | — | EP | disclosed |
| US-20200197348-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | ALMIRALL, S.A. (ES) | 2020-06-25 | — | — | US | disclosed |
| EP-3656379-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | Almirall S.A. (ES) | 2020-05-27 | — | — | EP | disclosed |
| EP-3641736-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | Almirall, S.A. (ES) | 2020-04-29 | — | — | EP | disclosed |
| WO-2018234584-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL, S.A. (ES) | 2018-12-27 | — | — | WO | disclosed |
| US-20160310457-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL, S.A. (ES) | 2016-10-27 | — | — | US | disclosed |
| EP-3079666-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | Almirall S.A. (ES) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086467-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
| US-20080299196-A1 | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester | ADITECH PHARMA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300217-A1 | Combination Therapy with Fumaric Acid Esters for the Treatment of Autoimmune and/or Inflammatory Disorders | ADITECH PHARMA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1951206-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | Aditech Pharma AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| EP-1940382-A2 | COMBINATION THERAPY WITH FUMARIC ACID ESTERS FOR THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | Aditech Pharma AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042035-A2 | COMBINATION THERAPY WITH FUMARIC ACID ESTERS FOR THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | ADITECH PHARMA AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042034-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | ADITECH PHARMA AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| EP-0666498-A2 | Silver halide photographic material | Agfa-Gevaert AG (DE) | 1995-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11602515-B2 | Pharmaceutical compositions comprising dimethyl fumarate | MGAM, SI, FH | TGFBR1 4080/4885TDP1 4197/4885CHRM1 2091/4885 |
| US-20080300217-A1 | Combination Therapy with Fumaric Acid Esters for the Treatment of Autoimmune and/or Inflammatory Disorders | FAH, FH, SLC16A1 | TGFBR1 2143/4885TDP1 3765/4885CHRM1 4718/4885 |
| US-20160310457-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE | MGAM, SI, FH | TGFBR1 4141/4885TDP1 4282/4885CHRM1 2112/4885 |
| US-20210330628-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | MGAM, SI, FH | TGFBR1 4151/4885TDP1 4258/4885CHRM1 2062/4885 |
| US-20200197348-A1 | Pharmaceutical Compositions Comprising Dimethyl Fumarate | MGAM, SI, FH | TGFBR1 4080/4885TDP1 4197/4885CHRM1 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.